IP Library Granted Patent US 9,970,060
Granted Patent B2
US 9,970,060 · App. 13/682,071 · Granted May 15, 2018

Quantitation and profiling of vaginal microflora

Inventors: Sergey Balashov (Hamilton, NJ); Martin E. Adelson (East Windsor, NJ); Charronne Davis (Mahwah, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
C12Q1/689C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,970,060
App. No.
13/682,071
Granted
May 15, 2018
Kind
B2
Abstract

Disclosed are methods of quantifying microflora in vaginal samples. Quantitative assessment of vaginal microflora by real-time PCR to create a profiling of Lactobacillus species, Gardnerella vaginalis, Atopobium vaginae, Megasphaera Type 1 and Type 2 and BVAB2 permits evaluation of bacterial vaginosis. Kits containing reagents for quantitative assessment of microflora are also disclosed.

Claims (27)

1. A kit comprising:

(a) a first forward primer, a first reverse primer and a first fluorescently-labeled probe against Gardnerella vaginalis , said first forward primer consisting of SEQ ID NO: 7, said first reverse primer consisting of SEQ ID NO: 8, and said first probe consisting of SEQ ID NO: 9;

(b) a second forward primer, a second reverse primer, and a second fluorescently-labeled probe against Lactobacillus iners , said second forward primer consisting of SEQ ID NO: 13, said second reverse primer consisting of SEQ ID NO: 14, and said second probe consisting of SEQ ID NO: 15; and

(c) an instruction for profiling vaginal microflora in a woman comprising instructions for calculating the relative amount of Lactobacillus iners and Gardnerella vaginalis in a biological sample obtained from the woman.

2. The kit of claim 1 , further comprising:

(d) a third forward primer, a third reverse primer and a third fluorescently-labeled probe against Atopobium vaginae , said third forward primer consisting of SEQ ID NO: 1, said third reverse primer consisting of SEQ ID NO: 2, and said third probe consisting of SEQ ID NO: 3;

(e) a fourth forward primer, a fourth reverse primer and a fourth fluorescently-labeled probe against BVAB2, said fourth forward primer consisting of SEQ ID NO: 4, said fourth reverse primer consisting of SEQ ID NO: 5, and said fourth probe consisting of SEQ ID NO: 6;

(f) a fifth, sixth and seventh fluorescently-labeled probes against Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus jensenii respectively, said fifth probe consisting of SEQ ID NO: 16, said sixth probe consisting of SEQ ID NO: 17 and said seventh probe consisting of SEQ ID NO: 18; and

(g) a fifth forward primer, a fifth reverse primer against Megasphaera , and an eighth and ninth fluorescently-labeled probe against Megasphaera Type 1 and Megasphaera Type 2, respectively, said fifth forward primer consisting of SEQ ID NO: 19, said fifth reverse primer consisting of SEQ ID NO: 20, and said eighth probe consisting of SEQ ID NO: 21 and said ninth probe consisting of SEQ ID NO: 22.

3. A method of diagnosing transitional vaginal microflora status in a woman, comprising the steps of:

(a) quantifying the amount of individual microflora for Lactobacillus crispatus, Lactobacillus gasseria, Lactobacillus jensenni, Lactobacillus iners, Gardnerella vaginalis, Atopobium vaginae, Megasphaera Type 1 , Megasphaera Type 2 and BVAB2 in a biological sample obtained from a woman,

wherein said quantifying step is performed by using a molecular assay selected from the group consisting of qPCR and multiplex qPCR;

(b) calculating the sum of said amount of individual microflora in said biological sample to obtain a total amount of microflora;

(c) calculating the sum of said amount of Lactobacillus iners and Gardnerella vaginalis in said biological sample;

(d) calculating the relative amount of said Lactobacillus iners and Gardnerella vaginalis in said biological sample by dividing said sum amount of Lactobacillus iners and Gardnerella vaginalis by said total amount of microflora,

wherein, said relative amount of Lactobacillus iners and Gardnerella vaginalis , when exceeding 50% of said total amount of microflora, is indicative of a transitional vaginal microflora; and

(e) diagnosing said woman with transitional vaginal microflora status based on said relative amount of Lactobacillus iners and Gardnerella vaginalis in said biological sample;

wherein:

the quantifying of Lactobacillus crispatus is performed using a multiplex qPCR and SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 16;

the quantifying of Lactobacillus gasseria is performed using a multiplex qPCR and SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 17;

the quantifying of Lactobacillus jensenni is performed using a multiplex qPCR and SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 18;

the quantifying of Lactobacillus iners is performed using a multiplex qPCR and SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15;

the quantifying of Atopobium vaginae is performed using SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3;

the quantifying of BVAB2 is performed using SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6;

the quantifying of Gardnerella vaginalis is performed using SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9;

the quantifying of Megasphaera Type 1 is performed using a multiplex qPCR and SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21; and

the quantifying of Megasphaera Type 2 is performed using a multiplex qPCR and SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 22.

Assignments (4)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (3)
Provisional Application 61629656 · Nov 23, 2011
Provisional Application 61668106 · Jul 5, 2012
Related Publication 20130316922A1 · Nov 28, 2013